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General Information 
Unless otherwise noted, reagents were obtained from commercial sources and used 
without further purification. Trimethylsilyl azide (TMSN3) was stored over 4Å molecular 
sieves at -20 ºC. Dry tetrahydrofuran (THF), dichloromethane (DCM), and toluene were 
obtained by passage through activated alumina columns under argon. All other solvents 
used are HPLC grade. TLC analysis of reaction mixtures was performed on Merck silica 
gel 60 F254 TLC plates and visualized by ultraviolet light, iodine and/or potassium 
permanganate stain. Flash chromatography was carried out with ICN SiliTech 32-63 D 
60 Å silica gel. 1H and 13C NMR spectra were recorded with Bruker AV-500, DRX-500, 
or AV-600 spectrometers and were referenced to residual 1H and 13C signals of the 
deuterated solvents, respectively (δH 7.26, δC 77.16 for chloroform and δH 5.32, δC 
54.00 for dichloromethane). 19F NMR spectra were recorded with Bruker AVQ-400 
spectrometer and were referenced to 19F signal of the hexafluorobenzene (δF -164.9). 
Chemical shifts (δ) are given in parts per million (ppm) and coupling constants values (J) 
are given in Hertz (Hz). Abbreviations for multiplicities are as follows: (s) singlet, (brs) 
broad singlet (d) doublet, (dd) doublet of doublets, (t) triplet, (q) quartet, (m) multiplet. 
Enantioselectivity was determined by chiral HPLC using Daicel Chiralpak AD-H, AS-H, 
IB, OD-H, or Regis (R,R) WHELK-O1 columns (all 0.46 cm x 25 cm). Generally, 
racemic samples were prepared by the procedure of Muñoz and co-workers using 
IPrAuCl (IPr = 1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene) and AgOTf.1 Mass 
spectral data were obtained via the Micro-Mass/Analytical Facility operated by the 
College of Chemistry, University of California, Berkeley. X-ray crystallographic analysis 
was carried out at the College of Chemistry X-Ray Crystallographic Facility (CHEXRAY, 




Preparation of ADC gold(I) complexes.  
5,5',6,6',7,7',8,8'-octahydro-3,3’-diido-2,2’-diamino-1,1’-binaphthyl and 5,5',6,6',7,7',8,8'-
octahydro-3,3’-aryl substituted 2,2’-diamino-1,1’-binaphthyls were prepared in 
procedures modified from Maruoka and coworkers.2 The synthesis 2-isocyanopyridine 
has been described previously.3 Isocyanopyridyl gold(I) complexes4 and ADC gold(I) 
complexes5 were prepared in procedures modified from Espinet and coworkers. A 




binaphthalene]-2,2'-diamine (S2)  
A flame-dried round bottom flask equipped with a teflon-coated stir bar containing S1 
(2.47 g, 4.54 mmol, 1.0 eq.), 3,5-bis(trifluoromethyl)-phenylboronic acid (2.98 g, 11.55 
mmol, 2.5 equiv), Pd(OAc)2 (48.3 mg, 0.215 mmol, 0.05 equiv), SPhos (179.5 mg, 0.437 
mmol, 0.10 equiv), and K3PO4 (4.38 g, 20.62 mmol, 4.5 equiv) was evacuated and 
backfilled with nitrogen. Dry toluene (110 mL) was added and the mixture was stirred 
vigorously at 100 °C overnight. The reaction mixture was then filtered through a pad of 
silica gel and Celite with dichloromethane eluent and concentrated. Purification by flash 
column chromatography (3:1 hexanes/dichloromethane) afforded S2 as a yellow foam 
(2.37 g, 3.31 mmol, 73% yield). Other 3,3’-disubstituted H8-BINAM derivatives were 
prepared analogously. 
1H NMR (600 MHz, CDCl3) δ 7.99 (s, 4H), 7.84 (s, 2H), 6.92 (s, 2H), 3.46 (br s, 4H), 
2.88 – 2.63 (m, 4H), 2.47 – 2.32 (m, 2H), 2.31 – 2.13 (m, 2H), 1.84 – 1.68 (m, 8H). 
13C NMR (151 MHz, CDCl3) δ 142.39, 138.70, 137.56, 132.21 (q, J = 33.3 Hz), 130.79, 
129.58, 128.70, 123.53 (q, J = 273.3 Hz), 122.83, 122.56, 120.92 – 120.82 (m), 29.41, 
27.31, 23.49 (d, J = 1.7 Hz), 23.29 (d, J = 1.7 Hz). 
19F NMR (376 MHz, CDCl3) δ -65.92. 






 To a solution of S34 (369 mg, 1.10 mmol, 2.2 equiv) in dry DCM (50 mL) was 
added S2 (358 mg, 0.499 mmol, 1.0 equiv) in one portion. The mixture was stirred in the 
dark overnight, until TLC analysis showed complete consumption of S2. The mixture 
was then concentrated in vacuo and chromatographed on silica gel (DCM → 20:1 
DCM/Et2O). Decomposition of unreacted S3 was observed as purple streaks on the 
column. The isolated product was further purified by vapor diffusion recrystallization 
from CHCl3 and pentane, affording transparent crystals. The mother liquor was decanted, 
the crystals were washed with hexanes, dissolved in DCM, and filtered through a fine frit 
Buchner filter funnel, and dried in vacuo to afford the desired product A5•(AuCl)2 as a 
white powder. The mother liquor was recrystallized by vapor diffusion again, and 
purified similarly to yield another crop of crystals (combined mass: 426 mg, 61% yield). 
Other ADC gold(I) complexes were prepared analogously. 
1H NMR (500 MHz, CD2Cl2) δ 13.57 (s, 2H), 8.78 (s, 2H), 8.25 (d, J = 5.0 Hz, 2H), 7.77 
(s, 4H), 7.74 (d, J = 10.0 Hz, 4H), 7.25 (s, 2H), 7.19 – 7.08 (m, 2H), 6.90 (d, J = 8.3 Hz, 
2H), 2.89 (t, J = 5.9 Hz, 4H), 2.70 – 2.57 (m, 2H), 2.43 (dt, J = 17.2, 5.1 Hz, 2H), 2.18 – 
1.81 (m, 8H). 
13C NMR (126 MHz, CDCl3) δ 195.16, 155.05, 144.82, 141.08, 138.94, 138.26, 135.83, 
135.45, 134.95, 133.56, 131.76, 131.40 (q, J = 33.1 Hz), 130.63, 123.28 (q, J = 273.4 
Hz), 120.60, 119.82, 115.07, 29.82, 28.58, 23.38, 23.00. 
19F NMR (376 MHz, CDCl3) δ -66.26. 




1H NMR (500 MHz, CD2Cl2) δ 13.44 (s, 2H), 8.36 (s, 2H), 8.29 – 8.22 (m, 2H), 7.80 – 
7.66 (m, 2H), 7.31 (d, J = 7.5 Hz, 4H), 7.24 (dt, J = 14.5, 7.1 Hz, 6H), 7.18 – 7.07 (m, 
4H), 6.86 (d, J = 8.3 Hz, 2H), 2.83 (d, J = 7.2 Hz, 4H), 2.61 (dt, J = 13.4, 6.5 Hz, 2H), 
2.52 – 2.27 (m, 2H), 2.01 (d, J = 10.6 Hz, 2H), 1.87 (td, J = 14.8, 12.9, 6.6 Hz, 6H). 
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13C NMR (126 MHz, CD2Cl2) δ 195.24, 155.17, 145.88, 139.79, 139.31, 138.51, 138.31, 
135.26, 134.99, 133.40, 132.65, 130.59, 128.69, 127.25, 120.12, 114.95, 30.10, 28.75, 
23.87, 23.46. 




1H NMR (400 MHz, CD2Cl2) δ 13.39 (s, 2H), 8.33 – 8.24 (m, 2H), 8.14 (s, 2H), 7.72 
(ddd, J = 8.3, 7.4, 1.9 Hz, 2H), 7.15 (s, 2H), 7.12 (ddd, J = 7.4, 5.1, 1.0 Hz, 2H), 6.94 – 
6.92 (m, 4H), 6.86 – 6.82 (m, 4H), 2.83 (t, J = 6.0 Hz, 4H), 2.72 – 2.52 (m, 2H), 2.37 (dt, 
J = 16.1, 5.1 Hz, 2H), 2.15 (s, 12H), 2.06 – 1.97 (m, 2H), 1.95 – 1.80 (m, 6H). 
13C NMR (126 MHz, CD2Cl2) δ 195.39, 155.07, 145.94, 139.43, 139.38, 138.55, 138.46, 
138.13, 135.32, 134.74, 133.29, 132.29, 128.65, 128.56, 120.13, 114.64, 30.15, 28.75, 
23.90, 23.49, 21.37. 




1H NMR (500 MHz, CD2Cl2) δ 13.44 (s, 2H), 8.27 (d, J = 4.2 Hz, 4H), 7.69 (t, J = 7.9 
Hz, 2H), 7.24 (t, J = 2.0 Hz, 2H), 7.19 (s, 2H), 7.10 (d, J = 1.9 Hz, 6H), 6.79 (d, J = 8.3 
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Hz, 2H), 2.86 (t, J = 5.8 Hz, 4H), 2.66 (d, J = 17.0 Hz, 2H), 2.45 (dd, J = 14.1, 9.0 Hz, 
2H), 2.05 (q, J = 7.7 Hz, 2H), 1.90 (dd, J = 20.1, 12.5 Hz, 6H), 1.13 (s, 36H). 
13C NMR (126 MHz, CD2Cl2) δ 195.54, 155.25, 150.99, 145.94, 139.63, 139.51, 138.69, 
138.38, 135.35, 134.63, 133.52, 132.28, 125.25, 121.03, 120.12, 114.55, 35.14, 31.55, 
30.24, 28.93, 23.98, 23.58. 




1H NMR (500 MHz, CD2Cl2) δ 13.39 (s, 2H), 8.42 (s, 2H), 8.24 (d, J = 5.1 Hz, 2H), 7.72 
(t, J = 7.9 Hz, 2H), 7.16 (s, 2H), 7.15 – 7.01 (m, 2H), 6.88 (d, J = 8.3 Hz, 2H), 6.46 (d, J 
= 2.5 Hz, 4H), 6.30 (t, J = 2.5 Hz, 2H), 3.61 (s, 12H), 2.83 (s, 4H), 2.58 (d, J = 17.1 Hz, 
2H), 2.38 (dd, J = 13.9, 8.8 Hz, 2H), 2.05 – 1.78 (m, 8H). 
13C NMR (126 MHz, CD2Cl2) δ 195.14, 160.96, 155.21, 145.82, 141.68, 139.41, 138.54, 
138.45, 135.26, 135.13, 133.33, 132.32, 120.17, 114.96, 108.50, 100.32, 55.84, 30.12, 
28.79, 23.86, 23.45. 
HRMS (ESI+): calc’d for [C48H48O4N6Au2Cl2]Na: 1259.2338, found: 1259.2367 
 
General procedure for preparation of substrates 
 
The synthesis of 1,3-disubstituted allenes by Pd-catalyzed cross-coupling was 
adapted from the procedure of Yoshida and coworkers.6 To a round bottom flask 
equipped with a Teflon-coated stir bar and condenser tube were added propargylic 
carbonate S4 or S5 (1.00 mmol scale), arylboronic acid (2 equiv.), K3PO4 (5 equiv.), 
Pd(PPh3)4 (10 mol%), 1,4-dioxane (6.7 mL) and H2O (3.3 mL) at room temperature, and 
the biphasic solution was heated to 100 °C with vigorous stirring for 5-15 min. The 
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reaction mixture was cooled to room temperature, then the aqueous phase was separated 
and extracted with DCM (10 mL). The combined organic layers were diluted with 
cyclohexane (75 mL), filtered through a pad of silica gel and Celite, then washed with 
brine and dried over MgSO4. The solvent was removed in vacuo, and the crude residue 
was chromatographed on silica gel with hexane as eluent (with Et2O as co-eluent for 
allenes bearing polar functionalities) to afford the pure allene 5. Allenes were stored in 
pentane at -20 ºC to prevent decomposition, then passed through short silica gel plugs 




1H NMR (600 MHz, CDCl3) δ 7.29 (d, J = 4.4 Hz, 4H), 7.17 (dq, J = 8.6, 4.2 Hz, 1H), 
6.09 (dq, J = 6.3, 3.2 Hz, 1H), 5.53 (p, J = 7.0 Hz, 1H), 1.78 (dd, J = 7.1, 3.3 Hz, 3H). 




1H NMR (600 MHz, CDCl3) δ 7.22 (d, J = 8.0 Hz, 2H), 7.14 (d, J = 7.8 Hz, 1H), 6.11 
(dq, J = 6.6, 3.3 Hz, 1H), 5.55 (p, J = 6.9 Hz, 1H), 2.37 (s, 4H), 1.82 (dd, J = 7.1, 3.3 Hz, 
3H). 
13C NMR (151 MHz, CDCl3) δ 205.82, 136.49, 132.16, 129.38, 126.67, 93.90, 89.57, 
21.29, 14.32. 




1H NMR (600 MHz, CDCl3) δ 7.48 (d, J = 8.0 Hz, 2H), 7.30 (d, J = 7.8 Hz, 2H), 6.11 
(dq, J = 6.4, 3.1 Hz, 1H), 5.56 (p, J = 6.9 Hz, 1H), 1.80 (dd, J = 7.1, 3.2 Hz, 3H), 0.28 (s, 
9H). 
13C NMR (151 MHz, CDCl3) δ 206.38, 138.84, 135.71, 133.72, 126.13, 94.12, 89.68, 
14.22, -0.95. 






1H NMR (600 MHz, CDCl3) δ 7.63 (dd, J = 8.1, 1.2 Hz, 2H), 7.58 (d, J = 8.2 Hz, 2H), 
7.47 (t, J = 7.7 Hz, 2H), 7.40 (d, J = 8.3 Hz, 2H), 7.37 (t, J = 7.4 Hz, 1H), 6.18 (dq, J = 
6.4, 3.2 Hz, 1H), 5.61 (p, J = 7.0 Hz, 1H), 1.85 (dd, J = 7.1, 3.2 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 206.35, 141.00, 139.62, 134.26, 128.88, 127.40, 127.29, 
127.18, 127.04, 93.80, 89.83, 14.26. 




1H NMR (600 MHz, CDCl3) δ 7.25 – 7.21 (m, 2H), 7.03 – 6.91 (m, 2H), 6.06 (dq, J = 
6.4, 3.2 Hz, 1H), 5.53 (p, J = 6.9 Hz, 1H), 1.78 (dd, J = 7.1, 3.2 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 205.70 (d, J = 2.4 Hz), 161.71 (d, J = 245.6 Hz), 130.92 
(d, J = 3.3 Hz), 127.95 (d, J = 8.0 Hz), 115.38 (d, J = 21.7 Hz), 92.97, 89.80, 14.05. 




1H NMR (500 MHz, CDCl3) δ 7.44 (d, J = 8.1 Hz, 2H), 7.18 (d, J = 8.2 Hz, 2H), 6.07 
(dq, J = 6.2, 3.2 Hz, 1H), 5.57 (p, J = 6.9, 6.3 Hz, 1H), 1.82 (dd, J = 7.2, 3.3 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 206.12, 134.14, 131.65, 128.24, 120.30, 93.32, 90.20, 
14.08. 




1H NMR (500 MHz, CDCl3) δ 7.56 (d, J = 8.0 Hz, 2H), 7.40 (d, J = 8.0 Hz, 2H), 6.14 (dt, 
J = 6.6, 3.5 Hz, 1H), 5.63 (p, J = 7.0 Hz, 1H), 1.84 (dd, J = 7.1, 3.3 Hz, 3H). 
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13C NMR (126 MHz, CDCl3) δ 207.03, 139.21, 128.66 (q, J = 32.3 Hz), 126.86, 125.58 
(q, J = 3.8 Hz), 123.40, 93.36, 90.38, 13.90. 




1H NMR (600 MHz, CDCl3) δ 7.27 (t, J = 7.6 Hz, 1H), 7.22 – 7.14 (m, 2H), 7.08 (d, J = 
7.6 Hz, 1H), 6.15 (dq, J = 6.5, 3.2 Hz, 1H), 5.60 (p, J = 7.0 Hz, 1H), 2.41 (s, 3H), 1.87 
(dd, J = 7.1, 3.2 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 206.08, 138.20, 135.03, 128.55, 127.61, 127.41, 123.96, 
94.12, 89.54, 21.47, 14.25. 




1H NMR (600 MHz, CDCl3) δ 7.24 (t, J = 7.9 Hz, 1H), 6.91 (d, J = 7.9 Hz, 1H), 6.87 (t, J 
= 2.1 Hz, 1H), 6.77 (dd, J = 8.2, 2.6 Hz, 1H), 6.09 (dq, J = 6.3, 3.1 Hz, 1H), 5.56 (p, J = 
7.0 Hz, 1H), 3.82 (s, 3H), 1.81 (dd, J = 7.1, 3.2 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 206.17, 159.96, 136.67, 129.59, 119.46, 112.46, 112.03, 
94.07, 89.78, 55.28, 14.19. 




1H NMR (600 MHz, CDCl3) δ 7.65 (d, J = 7.6 Hz, 2H), 7.56 (s, 1H), 7.51 – 7.44 (m, 3H), 
7.41 (dt, J = 12.4, 7.5 Hz, 2H), 7.34 (d, J = 7.6 Hz, 1H), 6.22 (dq, J = 6.6, 3.2 Hz, 1H), 
5.62 (p, J = 6.8 Hz, 1H), 1.86 (dd, J = 6.9, 3.0 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 206.25, 141.70, 141.31, 135.66, 129.07, 128.84, 127.42, 
127.31, 125.74, 125.73, 125.60, 94.11, 89.89, 14.25. 






1H NMR (600 MHz, CDCl3) δ 7.45 (t, J = 1.7 Hz, 1H), 7.31 (dt, J = 7.8, 1.7 Hz, 1H), 
7.20 (d, J = 7.7 Hz, 1H), 7.16 (t, J = 7.7 Hz, 1H), 6.04 (dq, J = 6.5, 3.2 Hz, 1H), 5.59 (p, J 
= 7.0 Hz, 1H), 1.81 (dd, J = 7.2, 3.2 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 206.38, 137.56, 130.10, 129.65, 129.52, 125.39, 122.87, 
93.15, 90.34, 14.11. 




1H NMR (500 MHz, CDCl3) δ 7.40 (d, J = 7.7 Hz, 1H), 7.23 – 7.06 (m, 3H), 6.37 – 6.26 
(m, 1H), 5.53 (p, J = 7.1 Hz, 1H), 2.40 (s, 2H), 1.82 (dt, J = 6.5, 2.9 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 206.86, 135.00, 133.27, 130.57, 127.31, 126.70, 126.17, 
91.42, 88.76, 20.01, 14.34. 




1H NMR (600 MHz, CDCl3) δ 7.29 (dt, J = 5.0, 2.2 Hz, 1H), 7.14 – 7.12 (m, 1H), 7.09 (s, 
1H), 6.22 (dp, J = 5.4, 2.8 Hz, 1H), 5.52 (p, J = 7.0 Hz, 1H), 1.82 (dt, J = 5.4, 2.5 Hz, 
3H). 
13C NMR (151 MHz, CDCl3) δ 206.28, 136.52, 126.43, 125.80, 120.35, 88.87, 88.70, 
14.35. 




1H NMR (500 MHz, CDCl3) δ 7.30 (dd, J = 4.4, 1.4 Hz, 4H), 7.19 (dtt, J = 8.7, 5.3, 2.5 
Hz, 1H), 6.13 (dtd, J = 6.1, 3.0, 1.4 Hz, 1H), 5.57 (qd, J = 6.7, 1.3 Hz, 1H), 2.26 – 2.08 
(m, 2H), 1.52 (qd, J = 7.4, 1.3 Hz, 2H), 0.98 (td, J = 7.3, 1.4 Hz, 3H). 
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13C NMR (126 MHz, CDCl3) δ 205.31, 135.25, 128.67, 126.73, 126.68, 95.05, 94.62, 
30.98, 22.55, 13.92. 




1H NMR (600 MHz, CDCl3) δ 7.28 (d, J = 8.4 Hz, 2H), 7.23 (d, J = 8.6 Hz, 2H), 6.08 
(dq, J = 6.4, 3.2 Hz, 1H), 5.57 (p, J = 7.0 Hz, 1H), 1.81 (dd, J = 7.1, 3.2 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 206.19, 133.74, 132.29, 128.78, 127.94, 93.27, 90.16, 
14.12. 
HRMS (EI+): calcd. for [C10H9Cl]+: 164.0395, found: 164.0394. 
 
 
3p, tert-butyl (3-(buta-1,2-dien-1-yl)phenyl)carbamate 
1H NMR (500 MHz, CDCl3) δ 7.29 – 7.17 (m, 3H), 6.98 (d, J = 7.3 Hz, 1H), 6.66 (s, 1H), 
6.06 (dq, J = 6.1, 3.3 Hz, 1H), 5.53 (p, J = 6.9, 6.2 Hz, 1H), 1.78 (dd, J = 6.9, 3.3 Hz, 
3H), 1.53 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 206.07, 152.86, 138.74, 135.99, 129.15, 121.48, 116.97, 
116.61, 93.97, 89.76, 80.51, 28.41, 14.17. 




1H NMR (500 MHz, CDCl3) δ 7.32 (s, 1H), 7.24 (t, J = 7.7 Hz, 1H), 7.18 (t, J = 6.6 Hz, 
2H), 6.07 (dq, J = 6.4, 3.0 Hz, 1H), 5.60 (p, J = 6.9 Hz, 1H), 1.83 (dd, J = 7.2, 3.2 Hz, 
3H). 
13C NMR (126 MHz, CDCl3) δ 206.38, 137.28, 134.60, 129.84, 126.77, 126.60, 124.96, 
93.24, 90.36, 14.13. 






1H NMR (600 MHz, CDCl3) δ 7.88 – 7.80 (m, 3H), 7.71 (s, 1H), 7.57 (dd, J = 8.5, 1.8 
Hz, 1H), 7.49 (dddd, J = 18.9, 8.1, 6.8, 1.4 Hz, 2H), 6.35 (dq, J = 6.4, 3.2 Hz, 1H), 5.68 
(p, J = 7.0 Hz, 1H), 1.90 (dd, J = 7.2, 3.3 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 206.67, 133.85, 132.70, 132.66, 128.25, 127.82, 127.76, 
126.26, 125.59, 125.41, 124.85, 94.51, 89.98, 14.31. 




1H NMR (600 MHz, CDCl3) δ 8.27 (d, J = 8.3 Hz, 1H), 7.96 – 7.84 (m, 1H), 7.76 (d, J = 
8.1 Hz, 1H), 7.62 – 7.58 (m, 1H), 7.53 (dddd, J = 19.2, 8.1, 6.8, 1.4 Hz, 2H), 7.48 (t, J = 
7.7 Hz, 1H), 6.83 (dq, J = 6.5, 3.2 Hz, 1H), 5.62 (p, J = 7.0 Hz, 1H), 1.89 (dd, J = 7.2, 3.3 
Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 207.48, 133.93, 131.22, 130.85, 128.63, 127.24, 125.92, 
125.62, 125.60, 125.26, 123.60, 90.58, 88.51, 14.18. 




1H NMR (600 MHz, CDCl3) δ 7.51 (dd, J = 18.6, 7.8 Hz, 2H), 7.25 (dt, J = 25.1, 7.5 Hz, 
2H), 6.59 (s, 1H), 6.23 (dq, J = 6.4, 3.2 Hz, 1H), 5.73 (p, J = 7.0 Hz, 1H), 1.89 (dd, J = 
7.2, 3.2 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 206.70, 155.01, 151.60, 129.28, 123.98, 122.81, 120.45, 
111.02, 103.53, 90.70, 85.18, 14.24. 






Allylic azide racemization studies 
 
PPh3(AuCl) (4.9 mg, 0.010 mmol, 10 mol%) or IPrAuCl (6.2 mg, 0.010 mmol, 10 
mol%) and silver triflate (2.8 mg, 0.011 mol%) were weighed in a dram vial and the 
appropriate solvent was added (1.0 mL). The heterogeneous mixture was sonicated for 5 
min using a commercial ultrasonic cleaner, and then filtered through glass fiber into a 
second dram vial, which had been pre-weighed with the allylic azide 4a (17.3 mg, 0.10 
mmol, 1.0 equiv.). The reaction vial was kept at room temperature for 24 h and then the 
reaction was quenched by addition of Et3N (ca. 200 µL, 1.4 mmol). The solvent was then 
removed in vacuo and the crude reaction mixture was passed through a short silica gel 
plug, washing with Et2O/hexanes. A sample of the product was then submitted for chiral 
HPLC analysis (WHELK column, 100% Hexanes, 0.50 mL/min, tR = major: 13.1 min, 
minor: 12.4 min.) The results are summarized below. 
All table entries are reported as % ee. 
L CHCl3 PhMe THF THF/CHCl3[a] THF/PhMe[a] 
PPh3 23 62 87 72 86 
IPr 46 73 88 84 87 
[a] 1:1 volumetric ratio. 
 With both achiral phosphine and carbene gold(I) catalysts, significant 
racemization is observed in chlorinated (CHCl3) and aromatic (PhMe) solvents, but 
almost none in ethereal solvent (THF). Furthermore, when THF is used as co-solvent 














Optimized procedure for gold(I)-catalyzed enantioselective hydrazidation 
Caution! This protocol generates hydrazoic acid (HN3), which is acutely toxic and 
extremely shock sensitive. Handle with care, and do not scale up significantly. 
 
A5•(AuCl)2 (7.0 mg, 0.005 mmol, 5 mol%) and silver triflate (3.8 mg, 0.015 
mmol, 15 mol%) were weighed in a dram vial and a 3:1 volumetric mixture of 
THF:CHCl3 was added (1.0 mL). The heterogeneous mixture was sonicated for 5 min 
using a commercial ultrasonic cleaner, and then filtered through glass fiber into a second 
dram vial. Substrate 5 (0.10 mmol, 1.0 equiv.) was weighed in a third dram vial and a 3:1 
volumetric mixture of THF:CHCl3 was added (1.0 mL). TMSN3 (39 µL, 0.30 mmol, 3 
equiv.) and water (3.6 µL, 0.20 mmol, 2 equiv.) were added via microscale syringe. Both 
vials were cooled to -10 ºC, and then the catalyst mixture was added to the reactant 
mixture via pipette. The temperature was maintained for 72 h and then the reaction was 
quenched by addition of Et3N (ca. 200 µL, 1.4 mmol). The reaction mixture was diluted 
with hexane (4 mL) and then passed through a short plug of silica gel, washing with 
hexane/Et2O. The solvent was then removed in vacuo and the crude reaction mixture was 
purified by flash column chromatography (hexane/Et2O, 4 mL Pasteur pipette column) to 
afford the pure product. 
The synthesis of 4a for racemization studies was initially carried out according to 
the procedure of Murahashi and coworkers.11 The maximum enantioselectivity achieved 
by utilizing this methodology was 80% ee. Subsequent racemization studies (including 
those published in the manuscript text) used 4a obtained from our optimized gold(I)-




1H NMR (600 MHz, CDCl3) δ 7.41 (d, J = 7.5 Hz, 2H), 7.34 (t, J = 7.6 Hz, 2H), 7.28 (t, J 
= 7.4 Hz, 1H), 6.61 (d, J = 15.8 Hz, 1H), 6.15 (dd, J = 15.8, 7.4 Hz, 1H), 4.18 (p, J = 6.8 
Hz, 1H), 1.38 (d, J = 6.7 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 136.17, 132.31, 128.78, 128.46, 128.21, 126.77, 59.81, 
20.37. 
HRMS (EI+): calcd. for [C10H11N3]+: 173.0953, found: 173.0953.  
HPLC: WHELK column, 100% Hexanes, 0.50 mL/min, tR = major: 13.1 min, minor: 
12.4 min. 90% ee. 





1H NMR (600 MHz, CDCl3) δ 7.30 (d, J = 7.8 Hz, 2H), 7.14 (d, J = 7.8 Hz, 2H), 6.57 (d, 
J = 15.8 Hz, 1H), 6.10 (dd, J = 15.8, 7.5 Hz, 1H), 4.16 (p, J = 6.8 Hz, 1H), 2.35 (s, 3H), 
1.37 (d, J = 6.7 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 138.14, 133.38, 132.26, 129.48, 127.41, 126.68, 59.95, 
21.36, 20.42. 
HRMS (EI+): calcd. for [C11H13N3]+: 187.1109, found: 187.1112.  
HPLC: AD-H column, 100% hexanes, 0.25 mL/min, tR = major: 16.3 min, minor: 17.3 




1H NMR (600 MHz, CDCl3) δ 7.50 (d, J = 7.9 Hz, 2H), 7.39 (d, J = 7.8 Hz, 2H), 6.60 (d, 
J = 15.8 Hz, 1H), 6.18 (dd, J = 15.8, 7.4 Hz, 1H), 4.18 (p, J = 6.8 Hz, 1H), 1.38 (d, J = 
6.7 Hz, 3H), 0.27 (s, 9H). 
13C NMR (151 MHz, CDCl3) δ 140.76, 136.54, 133.80, 132.32, 128.70, 126.05, 59.84, 
20.38, -1.02. 
HRMS (EI+): calcd. for [C13H19N3Si]+: 245.1348, found: 245.1348. 
HPLC: AD-H column, 100% hexanes, 0.50 mL/min, tR = major: 13.8 min, minor: 16.1 




1H NMR (600 MHz, CDCl3) δ 7.62 – 7.58 (m, 4H), 7.51 – 7.42 (m, 4H), 7.36 (t, J = 7.4 
Hz, 1H), 6.65 (d, J = 15.8 Hz, 1H), 6.20 (dd, J = 15.8, 7.4 Hz, 1H), 4.21 (p, J = 6.8 Hz, 
1H), 1.40 (d, J = 6.7 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 141.03, 140.71, 135.19, 131.86, 128.95, 128.54, 127.56, 
127.47, 127.21, 127.10, 59.86, 20.39. 
HRMS (EI+): calcd. for [C16H15N3]+: 249.1269, found: 249.1266. 
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HPLC: AD-H column, 100% hexanes, 1.00 mL/min, tR = major: 29.0 min, minor: 33.8 




1H NMR (600 MHz, CDCl3) δ 7.37 (dd, J = 8.5, 5.5 Hz, 2H), 7.02 (t, J = 8.6 Hz, 2H), 
6.57 (d, J = 15.8 Hz, 1H), 6.06 (dd, J = 15.8, 7.4 Hz, 1H), 4.16 (p, J = 6.8 Hz, 1H), 1.37 
(d, J = 6.7 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 162.72 (d, J = 247.6 Hz), 132.33 (d, J = 3.2 Hz), 131.11, 
128.33 (d, J = 8.1 Hz), 128.25 (d, J = 1.7 Hz), 115.72 (d, J = 21.7 Hz), 59.73, 20.35. 
HRMS (EI+): calcd. for [C10H10N3F]+: 191.0859, found: 191.0857. 
HPLC: AS-H column, 100% hexanes, 0.25 mL/min, tR = major: 41.4 min, minor: 34.3 




1H NMR (600 MHz, CDCl3) δ 7.48 (d, J = 8.3 Hz, 2H), 7.35 – 7.22 (m, 2H), 6.57 (d, J = 
15.8 Hz, 1H), 6.16 (dd, J = 15.8, 7.3 Hz, 1H), 4.19 (p, J = 6.8 Hz, 1H), 1.41 (d, J = 6.7 
Hz, 2H). 
13C NMR (151 MHz, CDCl3) δ 135.15, 131.92, 131.05, 129.34, 128.28, 122.06, 59.61, 
20.27. 
HRMS (EI+): calcd. for [C10H10N3Br]+: 251.0058, found: 251.0058. 
HPLC: AD-H column, 100% hexanes, 0.50 mL/min, tR = major: 23.5 min, minor: 25.2 




1H NMR (600 MHz, CDCl3) δ 7.59 (d, J = 8.1 Hz, 2H), 7.49 (d, J = 8.0 Hz, 2H), 6.64 (d, 
J = 15.8 Hz, 1H), 6.24 (dd, J = 15.8, 7.1 Hz, 1H), 4.20 (p, J = 6.8 Hz, 1H), 1.40 (d, J = 
6.7 Hz, 3H). 
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13C NMR (151 MHz, CDCl3) δ 139.71, 131.24, 130.75, 130.05 (q, J = 32.5 Hz), 126.94, 
125.76 (q, J = 3.9 Hz), 59.42, 20.19. 
HRMS (EI+): calcd. for [C11H10N3F3]+: 241.0827, found: 241.0827. 
HPLC: AS-H column, 100% hexanes, 0.50 mL/min, tR = major: 14.8 min, minor: 13.3 




1H NMR (600 MHz, CDCl3) δ 7.25 – 7.18 (m, 3H), 7.09 (d, J = 7.0 Hz, 1H), 6.57 (d, J = 
15.8 Hz, 1H), 6.13 (dd, J = 15.8, 7.4 Hz, 1H), 4.17 (p, J = 6.8 Hz, 1H), 2.35 (s, 3H), 1.37 
(d, J = 6.6 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 138.38, 136.13, 132.45, 129.02, 128.69, 128.25, 127.47, 
123.96, 59.88, 21.52, 20.41. 
HRMS (EI+): calcd. for [C11H13N3]+: 187.1109, found: 187.1110. 
HPLC: AD-H column, 100% hexanes, 0.25 mL/min, tR = major: 30.2 min, minor: 32.4 




1H NMR (600 MHz, CDCl3) δ 7.29 – 7.24 (m, 1H), 7.02 (d, J = 7.7 Hz, 1H), 6.95 (s, 1H), 
6.85 (dd, J = 8.2, 2.0 Hz, 1H), 6.60 (d, J = 15.8 Hz, 1H), 6.16 (dd, J = 15.8, 7.4 Hz, 1H), 
4.20 (p, J = 6.8 Hz, 1H), 3.85 (s, 3H), 1.40 (d, J = 6.7 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 160.01, 137.64, 132.19, 129.78, 128.81, 119.44, 113.92, 
112.09, 59.76, 55.41, 20.36. 
HRMS (EI+): calcd. for [C11H13N3O]+: 203.1059, found: 203.1058. 
HPLC: AD-H column, 100% hexanes, 1.00 mL/min, tR = major: 23.0 min, minor: 25.5 






1H NMR (600 MHz, CDCl3) δ 7.62 (m, 3H), 7.52 (d, J = 7.2 Hz, 1H), 7.47 (t, J = 7.6 Hz, 
2H), 7.40 (m, 3H), 6.69 (d, J = 15.8 Hz, 1H), 6.23 (dd, J = 15.8, 7.4 Hz, 1H), 4.21 (p, J = 
6.8 Hz, 1H), 1.41 (d, J = 6.7 Hz, 3H).  
13C NMR (151 MHz, CDCl3) δ 141.84, 141.04, 136.63, 132.20, 129.20, 128.92, 128.85, 
127.58, 127.30, 127.09, 125.68, 125.62, 59.81, 20.38. 
HRMS (EI+): calcd. for [C16H15N3]+: 249.1266, found: 249.1266. 
HPLC: WHELK column, 100% hexanes 0.75 mL/min, tR = major: 22.0 min, minor: 20.2 




1H NMR (600 MHz, CDCl3) δ 7.55 (s, 1H), 7.39 (d, J = 7.8 Hz, 1H), 7.30 (d, J = 7.7 Hz, 
1H), 7.20 (t, J = 7.8 Hz, 1H), 6.53 (d, J = 15.7 Hz, 1H), 6.15 (dd, J = 15.8, 7.2 Hz, 1H), 
4.17 (p, J = 6.8 Hz, 1H), 1.38 (d, J = 6.7 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 138.35, 131.08, 130.74, 130.29, 130.11, 129.61, 125.47, 
122.98, 59.51, 20.28. 
HRMS (EI+): calcd. for [C10H10N3Br]+: 251.0058, found: 251.0062. 
HPLC: WHELK column, 100% hexanes, 0.25 mL/min, tR = major: 40.0 min, minor: 37.7 
min. 88% ee. 
 
 
4l, (R,E)-1-(3-azidobut-1-en-1-yl)-2-methylbenzene  
1H NMR (600 MHz, CDCl3) δ 7.47 – 7.42 (m, 1H), 7.22 – 7.15 (m, 3H), 6.82 (d, J = 15.6 
Hz, 1H), 6.02 (dd, J = 15.6, 7.5 Hz, 1H), 4.20 (p, J = 6.8 Hz, 1H), 2.37 (s, 3H), 1.39 (d, J 
= 6.7 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 135.79, 135.41, 130.47, 130.38, 129.78, 128.10, 126.29, 
126.00, 60.04, 20.46, 19.95. 
HRMS (EI+): calcd. for [C11H13N3]+: 187.1109, found: 187.1110.  
HPLC: AD-H column, 100% hexanes, 0.50 mL/min, tR = major: 12.4 min, minor: 13.3 






1H NMR (600 MHz, CDCl3) δ 7.29 (dd, J = 5.1, 2.9 Hz, 1H), 7.24 – 7.12 (m, 2H), 6.61 
(d, J = 15.7 Hz, 1H), 6.00 (dd, J = 15.8, 7.4 Hz, 1H), 4.14 (p, J = 6.9 Hz, 1H), 1.36 (d, J 
= 6.7 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 138.79, 128.31, 126.42, 126.40, 125.10, 123.17, 59.81, 
20.36. 
HRMS (EI+): calcd. for [C8H9N3S]+: 179.0517, found: 179.0517. 
HPLC: WHELK column, 100% hexanes, 0.30 mL/min, tR = major: 27.7 min, minor: 25.9 




1H NMR (600 MHz, CDCl3) δ 7.41 (d, J = 7.5 Hz, 2H), 7.34 (t, J = 7.6 Hz, 2H), 7.30 – 
7.26 (m, 1H), 6.61 (d, J = 15.8 Hz, 1H), 6.11 (dd, J = 15.8, 8.1 Hz, 1H), 4.01 (q, J = 7.3 
Hz, 1H), 1.69 – 1.61 (m, 1H), 1.61 –1.55 (m, 1H), 1.50 – 1.36 (m, 2H), 0.95 (t, J = 7.4 
Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 136.08, 133.12, 128.65, 128.09, 127.29, 126.64, 64.66, 
36.85, 19.17, 13.76. 
HRMS (EI+): calcd. for [C12H15N3]+: 201.1266, found: 201.1264. 
HPLC: WHELK column, 100% hexanes, 0.50 mL/min, tR = major: 11.7 min, minor: 11.0 
min. 66% ee. 
 
The following products were omitted from the main text due to space considerations. 
 
4o, (R,E)-1-(3-azidobut-1-en-1-yl)-4-chlorobenzene 
1H NMR (600 MHz, CDCl3) δ 7.34 – 7.28 (m, 4H), 6.55 (d, J = 15.8 Hz, 1H), 6.12 (dd, J 
= 15.8, 7.3 Hz, 1H), 4.20 – 4.13 (m, 1H), 1.38 (d, J = 6.7 Hz, 3H).   




HRMS (EI+): calcd. for [C10H10N3Cl]+: 207.0563, found: 207.0561. 
HPLC: AD-H column, 100% hexanes, 0.25 mL/min, tR = major: 41.3 min, minor: 42.9 
min. 89% ee. 
 
 
4p, tert-butyl (R,E)-(3-(3-azidobut-1-en-1-yl)phenyl)carbamate 
1H NMR (500 MHz, CDCl3) δ 7.53 (s, 1H), 7.28 – 7.20 (m, 1H), 7.21 – 7.14 (m, 1H), 
7.07 (dt, J = 7.5, 1.3 Hz, 1H), 6.56 (d, J = 15.7 Hz, 1H), 6.49 (s, 1H), 6.15 (dd, J = 15.8, 
7.4 Hz, 1H), 4.16 (p, J = 6.8 Hz, 1H), 1.52 (s, 9H), 1.36 (d, J = 6.7 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 152.83, 138.88, 137.12, 132.04, 129.30, 128.91, 121.59, 
118.27, 116.61, 80.77, 59.73, 28.48, 20.30. 
HRMS (EI+): calcd. for [C15H20N4O2]+: 288.1586, found: 288.1582. 
HPLC: AS-H column, 99:1 hexanes:isopropanol, 1.00 mL/min, tR = major: 15.1 min, 




1H NMR (600 MHz, CDCl3) δ 7.42 (s, 1H), 7.28 (m, 3H), 6.57 (d, J = 15.8 Hz, 1H), 6.18 
(dd, J = 15.8, 7.3 Hz, 1H), 4.20 (p, J = 6.8 Hz, 1H), 1.41 (d, J = 6.7 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 138.09, 134.80, 130.86, 130.08, 130.01, 128.17, 126.69, 
125.02, 59.51, 20.27. 
HRMS (EI+): calcd. for [C10H10N3Cl]+: 207.0563, found: 207.0561. 
HPLC: WHELK column, 100% hexanes, 0.30 mL/min, tR = major: 24.9 min, minor: 22.7 
min. 87% ee. 
 
 
4r, (R,E)-2-(3-azidobut-1-en-1-yl)naphthalene  
1H NMR (600 MHz, CDCl3) δ 7.81 (m, 3H), 7.77 (s, 1H), 7.61 (d, J = 8.5 Hz, 1H), 7.47 
(m, 2H), 6.77 (d, J = 15.8 Hz, 1H), 6.28 (dd, J = 15.8, 7.4 Hz, 1H), 4.24 (p, J = 6.8 Hz, 
1H), 1.43 (d, J = 6.7 Hz, 3H). 
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13C NMR (151 MHz, CDCl3) δ 133.65, 133.62, 133.33, 132.39, 128.81, 128.46, 128.17, 
127.82, 126.99, 126.52, 126.26, 123.63, 59.90, 20.41. 
HRMS (EI+): calcd. for [C14H13N3]+: 223.1109, found: 223.1109. 
HPLC: WHELK column, 100% hexanes, 0.75 mL/min, tR = major: 26.5 min, minor: 24.2 




1H NMR (600 MHz, CDCl3) δ 8.10 (d, J = 8.3 Hz, 1H), 7.87 (d, J = 8.0 Hz, 1H), 7.82 (d, 
J = 8.2 Hz, 1H), 7.61 (d, J = 7.1 Hz, 1H), 7.53 (dt, J = 14.7, 7.1 Hz, 2H), 7.46 (t, J = 7.6 
Hz, 1H), 7.36 (d, J = 15.5 Hz, 1H), 6.18 (dd, J = 15.5, 7.3 Hz, 1H), 4.31 (p, J = 6.8 Hz, 
1H), 1.46 (d, J = 6.7 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 134.02, 133.72, 131.72, 131.26, 129.72, 128.72, 128.56, 
126.38, 126.03, 125.70, 124.33, 123.82, 59.91, 20.44. 
HRMS (EI+): calcd. for [C14H13N3]+: 223.1109, found: 223.1108. 
HPLC: WHELK column, 100% hexanes, 0.50 mL/min, tR = major: 26.4 min, minor: 23.1 




1H NMR (500 MHz, CDCl3) δ 8.16 (d, J = 7.5 Hz, 1H), 8.08 (dd, J = 8.3, 2.3 Hz, 1H), 
7.97 – 7.86 (m, 2H), 7.84 (td, J = 7.5, 2.4 Hz, 1H), 7.18 (dd, J = 15.7, 2.4 Hz, 1H), 7.03 
(ddd, J = 15.7, 7.1, 2.4 Hz, 1H), 4.84 (h, J = 6.9, 6.2 Hz, 1H), 2.05 (dd, J = 6.8, 2.4 Hz, 
3H). 
13C NMR (126 MHz, CDCl3) δ 154.94, 153.49, 130.33, 128.84, 125.00, 123.05, 121.16, 
120.27, 111.10, 105.79, 59.17, 20.18. 
HRMS (EI+): calcd. for [C12H11N3O]+: 213.0902, found: 213.0902. 
HPLC: AD-H column, 100% hexanes, 0.50 mL/min, tR = major: 23.7 min, minor: 28.7 




Optimized procedure for gold(I)-catalyzed enantioselective hydroamination 
 
A4•(AuCl)2 (3.1 mg, 0.0025 mmol, 5 mol%) and silver triflate (1.6 mg, 0.006) 
mmol, 12 mol%) were weighed in a dram vial and a 1,4-dioxane (anhydrous) was added 
(1.0 mL). The heterogeneous mixture was sonicated for 5 min using a commercial 
ultrasonic cleaner, and then filtered through glass fiber into a second dram vial, which 
had been pre-weighed with the appropriate substrate 5 (0.05 mmol, 1.0 equiv.) and tert-
butyl carbamate (17.6 mg, 0.15 mmol, 3 equiv.) The reaction vial was kept at room 
temperature for 24 h and then the reaction was quenched by addition of Et3N (ca. 200 µL, 
1.4 mmol). The reaction solvent was then removed in vacuo and the crude reaction 
mixture was purified by flash column chromatography (hexane/Et2O, silica gel, 4 mL 
Pasteur pipette column) to afford the pure product. 
 
 
5a, tert-butyl (S,E)-(4-phenylbut-3-en-2-yl)carbamate14 
1H NMR (600 MHz, CDCl3) δ 7.36 (d, J = 8.3 Hz, 2H), 7.30 (t, J = 7.7 Hz, 2H), 7.23 (t, J 
= 6.8 Hz, 1H), 6.50 (d, J = 16.1 Hz, 1H), 6.16 (dd, J = 15.8, 5.9 Hz, 1H), 4.56 (brs, 1H), 
4.41 (brs, 1H), 1.46 (s, 9H), 1.31 (d, J = 6.7 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 155.26, 137.00, 131.88, 129.33, 128.67, 127.61, 126.51, 
79.53, 48.01, 28.58, 21.29. 
HPLC: AD-H column, 95:5 hexanes:isopropanol, 1.00 mL/min, tR = major: 8.3 min, 
minor: 6.6 min. 89% ee. 
[α]D20 −19.0° (c 1.0, CHCl3); Lit.: [α]D20 −60.9° (c 1.08, CHCl3, S-enantiomer, 98% ee) 
 
 
5b, tert-butyl (S,E)-(4-(p-tolyl)but-3-en-2-yl)carbamate 
1H NMR (600 MHz, CDCl3) δ 7.25 (d, J = 8.7 Hz, 2H), 7.11 (d, J = 7.7 Hz, 2H), 6.46 (d, 
J = 15.9 Hz, 1H), 6.10 (dd, J = 16.0, 5.8 Hz, 1H), 4.54 (brs, 1H), 4.39 (brs, 1H), 2.33 (s, 
3H), 1.46 (d, J = 2.0 Hz, 9H), 1.30 (d, J = 6.7 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 155.27, 137.42, 134.19, 130.81, 129.37, 129.21, 126.41, 
79.50, 48.00, 28.59, 21.31. 
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HRMS (EI+): calcd. for [C16H23NO2]+: 261.1729, found: 261.1728. 
HPLC: AD-H column, 95:5 hexanes:isopropanol, 1.00 mL/min, tR = major: 9.8 min, 
minor: 6.3 min. 80% ee. 
 
 
5c, tert-butyl (S,E)-(4-(4-(trimethylsilyl)phenyl)but-3-en-2-yl)carbamate 
1H NMR (600 MHz, CDCl3) δ 7.46 (d, J = 7.8 Hz, 2H), 7.34 (d, J = 7.6 Hz, 2H), 6.49 (d, 
J = 15.9 Hz, 1H), 6.18 (dd, J = 15.8, 5.9 Hz, 1H), 4.55 (brs, 1H), 4.41 (brs, 1H), 1.46 (s, 
9H), 1.31 (d, J = 6.8 Hz, 3H), 0.26 (s, 9H). 
13C NMR (151 MHz, CDCl3) δ 155.26, 139.91, 137.42, 133.72, 132.18, 129.33, 125.83, 
79.55, 48.04, 28.59, 21.28, -0.99. 
HRMS (EI+): calcd. for [C18H29NO2Si]+: 319.1968, found: 319.1959. 
HPLC: AD-H column, 95:5 hexanes:isopropanol, 1.00 mL/min, tR = major: 5.9 min, 
minor: 5.0 min. 73% ee. 
 
 
5d, tert-butyl (S,E)-(4-([1,1'-biphenyl]-4-yl)but-3-en-2-yl)carbamate 
1H NMR (500 MHz, CDCl3) δ 7.64 – 7.52 (m, 4H), 7.44 (dt, J = 7.5, 3.5 Hz, 4H), 7.38 – 
7.31 (m, 1H), 6.53 (d, J = 15.9 Hz, 1H), 6.20 (dd, J = 15.6, 5.8 Hz, 1H), 4.57 (brs, 1H), 
4.43 (brs, 1H), 1.47 (s, 9H), 1.33 (d, J = 6.8 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 155.24, 140.81, 140.36, 136.00, 131.97, 128.91, 128.83, 
127.42, 127.36, 127.05, 126.93, 79.57, 48.01, 28.58, 21.30. 
HRMS (EI+): calcd. for [C21H25NO2]+: 323.1885, found: 323.1885. 
HPLC: AD-H column, 95:5 hexanes:isopropanol, 1.00 mL/min, tR = major: 14.1 min, 
minor: 9.7 min. 64% ee. 
 
 
5e, tert-butyl (S,E)-(4-(4-fluorophenyl)but-3-en-2-yl)carbamate 
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1H NMR (600 MHz, CDCl3) δ 7.40 – 7.28 (m, 2H), 7.11 – 6.92 (m, 2H), 6.45 (d, J = 15.9 
Hz, 1H), 6.06 (dd, J = 15.8, 5.7 Hz, 1H), 4.54 (brs, 1H), 4.38 (brs, 1H), 1.46 (s, 9H), 1.30 
(d, J = 6.8 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 162.39 (d, J = 246.6 Hz), 155.24, 133.14 (d, J = 3.3 Hz), 
131.67, 128.17, 127.99 (d, J = 8.0 Hz), 115.55 (d, J = 21.5 Hz), 79.58, 47.96, 28.58, 
21.27. 
HRMS (EI+): calcd. for [C15H20FNO2]+: 265.1478, found: 265.1482. 
HPLC: AD-H column, 95:5 hexanes:isopropanol, 1.00 mL/min, tR = major: 8.6 min, 
minor: 7.1 min. 87% ee. 
 
 
5f, tert-butyl (S,E)-(4-(4-bromophenyl)but-3-en-2-yl)carbamate15 
1H NMR (600 MHz, CDCl3) δ 7.42 (d, J = 8.5 Hz, 2H), 7.21 (d, J = 8.5 Hz, 2H), 6.42 (d, 
J = 15.9 Hz, 1H), 6.14 (dd, J = 15.9, 5.8 Hz, 1H), 4.54 (brs, 1H), 4.38 (brs, 1H), 1.45 (s, 
9H), 1.30 (d, J = 6.8 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 155.22, 135.96, 132.76, 131.76, 128.17, 128.05, 121.34, 
79.64, 47.96, 28.57, 21.19. 
HRMS (EI+): calcd. for [C15H20BrNO2]+: 325.0677, found: 325.0677. 
HPLC: AD-H column, 95:5 hexanes:isopropanol, 1.00 mL/min, tR = major: 11.0 min, 
minor: 8.0 min. 92% ee. 
 
 
5g, tert-butyl (S,E)-(4-(4-(trifluoromethyl)phenyl)but-3-en-2-yl)carbamate 
1H NMR (600 MHz, CDCl3) δ 7.55 (d, J = 8.2 Hz, 2H), 7.44 (d, J = 8.2 Hz, 2H), 6.52 (d, 
J = 15.9 Hz, 1H), 6.25 (dd, J = 15.8, 5.7 Hz, 1H), 4.56 (brs, 1H), 4.42 (brs, 1H), 1.46 (s, 
9H), 1.32 (d, J = 6.9 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 155.21, 140.51, 134.69, 129.43 (q, J = 32.6 Hz), 128.01, 
126.67, 125.62 (q, J = 3.8 Hz), 124.33 (q, J = 271.8 Hz), 79.72, 47.96, 28.56, 21.13. 
HRMS (EI+): calcd. for [C16H20F3NO2]+: 315.1446, found: 315.1440. 
HPLC: AD-H column, 95:5 hexanes:isopropanol, 1.00 mL/min, tR = major: 9.6 min, 





5h, tert-butyl (S,E)-(4-(m-tolyl)but-3-en-2-yl)carbamate 
1H NMR (600 MHz, CDCl3) δ 7.22 – 7.13 (m, 3H), 7.05 (d, J = 7.4 Hz, 1H), 6.46 (d, J = 
15.9 Hz, 1H), 6.14 (dd, J = 16.2, 5.4 Hz, 1H), 4.55 (brs, 1H), 4.41 (brs, 1H), 2.34 (s, 3H), 
1.46 (s, 9H), 1.31 (d, J = 6.8 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 155.08, 138.01, 136.75, 131.48, 129.23, 128.37, 128.22, 
127.03, 123.49, 79.32, 47.82, 28.40, 21.32, 21.11. 
HRMS (EI+): calcd. for [C16H23NO2]+: 261.1729, found: 261.1723. 
HPLC: AD-H column, 95:5 hexanes:isopropanol, 1.00 mL/min, tR = major: 7.0 min, 
minor: 5.9 min. 83% ee. 
 
 
5i, tert-butyl (S,E)-(4-(3-methoxyphenyl)but-3-en-2-yl)carbamate15 
1H NMR (600 MHz, CDCl3) δ 7.22 (t, J = 7.9 Hz, 1H), 6.95 (dt, J = 7.5, 1.1 Hz, 1H), 
6.92 – 6.86 (m, 1H), 6.78 (ddd, J = 8.1, 2.6, 0.9 Hz, 1H), 6.46 (d, J = 15.9 Hz, 1H), 6.15 
(dd, J = 15.6, 5.7 Hz, 1H), 4.56 (brs, 1H), 4.41 (brs, 1H), 3.81 (s, 3H), 1.46 (s, 9H), 1.31 
(d, J = 6.6 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 159.77, 155.07, 138.29, 132.03, 129.44, 129.06, 119.00, 
113.14, 111.66, 79.37, 55.17, 47.82, 28.39, 21.07. 
HRMS (EI+): calcd. for [C16H23NO2]+: 277.1678, found: 277.1677. 
HPLC: AD-H column, 95:5 hexanes:isopropanol, 1.00 mL/min, tR = major: 12.3 min, 
minor: 9.0 min. 78% ee. 
 
 
5j, tert-butyl (S,E)-(4-([1,1'-biphenyl]-3-yl)but-3-en-2-yl)carbamate 
1H NMR (600 MHz, CDCl3) δ 7.64 – 7.55 (m, 3H), 7.48 – 7.42 (m, 3H), 7.41 – 7.31 (m, 
3H), 6.57 (d, J = 15.8 Hz, 1H), 6.23 (dd, J = 15.8, 6.8 Hz, 1H), 4.57 (brs, 1H), 4.44 (brs, 
1H), 1.47 (s, 9H), 1.33 (d, J = 6.8 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 155.26, 141.73, 141.25, 137.48, 132.32, 129.27, 129.09, 
128.89, 127.49, 127.31, 126.52, 125.46, 125.41, 79.59, 48.05, 28.60, 21.32. 
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HRMS (EI+): calcd. for [C21H25NO2]+: 323.1885, found: 323.1880. 
HPLC: AD-H column, 95:5 hexanes:isopropanol, 1.00 mL/min, tR = major: 13.6 min, 
minor: 9.1 min. 72% ee. 
 
 
5k, tert-butyl (S,E)-(4-(3-bromophenyl)but-3-en-2-yl)carbamate 
1H NMR (600 MHz, CDCl3) δ 7.51 (t, J = 1.8 Hz, 1H), 7.34 (d, J = 8.0 Hz, 1H), 7.25 (d, 
J = 6.4 Hz, 1H), 7.16 (t, J = 7.8 Hz, 1H), 6.42 (d, J = 15.9 Hz, 1H), 6.16 (dd, J = 15.8, 5.7 
Hz, 1H), 4.55 (brs, 1H), 4.40 (brs, 1H), 1.46 (s, 9H), 1.30 (d, J = 6.8 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 155.20, 139.19, 133.56, 130.45, 130.16, 129.34, 127.91, 
125.24, 122.86, 79.65, 47.90, 28.57, 21.20. 
HRMS (EI+): calcd. for [C15H20BrNO2]+: 325.0677, found: 325.0672. 
HPLC: AD-H column, 95:5 hexanes:isopropanol, 1.00 mL/min, tR = major: 8.3 min, 
minor: 6.7 min. 85% ee. 
 
 
5l, tert-butyl (S,E)-(4-(o-tolyl)but-3-en-2-yl)carbamate15 
1H NMR (600 MHz, CDCl3) δ 7.44 – 7.34 (m, 1H), 7.18 – 7.08 (m, 3H), 6.70 (d, J = 15.7 
Hz, 1H), 6.02 (dd, J = 15.7, 5.7 Hz, 1H), 4.55 (brs, 1H), 4.41 (brs, 1H), 2.33 (s, 3H), 1.46 
(s, 9H), 1.32 (d, J = 6.8 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 155.27, 136.19, 135.57, 133.28, 130.36, 127.53, 127.27, 
126.19, 125.82, 79.52, 48.26, 28.60, 21.39, 19.92. 
HRMS (EI+): calcd. for [C16H23NO2]+: 261.1729, found: 261.1726. 
HPLC: AD-H column, 95:5 hexanes:isopropanol, 1.00 mL/min, tR = major: 6.9 min, 
minor: 6.2 min. 80% ee. 
 
 
5m, tert-butyl (S,E)-(4-(thiophen-3-yl)but-3-en-2-yl)carbamate 
26 
 
1H NMR (600 MHz, CDCl3) δ 7.26 – 7.24 (m, 1H), 7.18 (d, J = 4.4 Hz, 1H), 7.13 (d, J = 
2.9 Hz, 1H), 6.51 (d, J = 15.9 Hz, 1H), 6.01 (dd, J = 15.8, 5.7 Hz, 1H), 4.52 (brs, 1H), 
4.37 (brs, 1H), 1.46 (s, 9H), 1.29 (d, J = 6.8 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 155.24, 139.57, 131.77, 126.12, 125.11, 123.62, 122.05, 
79.54, 47.91, 28.59, 21.25. 
HRMS (EI+): calcd. for [C13H19NO2S]+: 253.1137, found: 253.1131. 
HPLC: AD-H column, 95:5 hexanes:isopropanol, 1.00 mL/min, tR = major: 10.1 min, 
minor: 7.9 min. 77% ee. 
 
 
5n, tert-butyl (S,E)-(1-phenylhex-1-en-3-yl)carbamate 
1H NMR (600 MHz, CDCl3) δ 7.36 (d, J = 8.5 Hz, 2H), 7.30 (t, J = 7.8 Hz, 2H), 7.22 (t, J 
= 7.3 Hz, 1H), 6.50 (d, J = 15.8 Hz, 1H), 6.08 (dd, J = 16.5, 6.8 Hz, 1H), 4.54 (brs, 1H), 
4.27 (brs, 1H), 1.59 – 1.53 (m, 2H), 1.46 (s, 9H), 1.44 – 1.36 (m, 2H), 0.94 (t, J = 7.4 Hz, 
3H). 
13C NMR (151 MHz, CDCl3) δ 155.47, 137.11, 130.97, 130.02, 128.66, 127.56, 126.51, 
79.48, 52.46, 37.95, 28.59, 19.22, 14.04. 
HPLC: AD-H column, 95:5 hexanes:isopropanol, 1.00 mL/min, tR = major: 8.6 min, 














Products obtained from other nucleophiles 
 
6, tert-butyl (S,E)-2-(4-phenylbut-3-en-2-yl)hydrazine-1-carboxylate 
The spectral data are consistent with those previously reported.16 
HPLC: AD-H column, 95:5 hexanes:isopropanol, 1.00 mL/min, tR = major: 10.2 min, 
minor: 12.1 min. 65% ee. 
[α]D20 −68.5° (c 0.68, CHCl3); Lit.: [α]D20 −143° (c 0.99, CHCl3, S-enantiomer, 94% ee) 
 
 
7, (S,E)-N-(4-phenylbut-3-en-2-yl)aniline  
The spectral data are consistent with those previously reported.17 
HPLC: IB column, 99:1 hexanes:isopropanol, 1.00 mL/min, tR = major: 11.0 min, minor: 
13.1 min. 30% ee. 
[α]D20 −32.5° (c 0.36, CHCl3); Lit.: [α]D20 +4.4° (c 1.0, CHCl3, R-enantiomer, 98.5% ee) 
 
Preparation of Boc-protected amine product 
 
(R)-5a, tert-butyl (R,E)-(4-phenylbut-3-en-2-yl)carbamate 
The title compound was prepared in a procedure modified from Rueping18 and 
Atlan.19 Crude azide 4a (from 0.1 mmol of allene 3a) was dissolved in a mixture of THF 
(1.5 mL) and H2O (0.3 mL) and treated with PPh3 (57.7 mg, 0.22 mmol, 2.2 equiv.). The 
reaction mixture was stirred at room temperature until TLC analysis showed full 
consumption of starting material. The reaction mixture was then made basic with KOH 
(2M) and di-tert-butyldicarbonate was added (92 µL, 0.4 mmol, 4.0 equiv.). The reaction 
mixture was stirred at room temperature for 24 hours and then THF was removed in 
vacuo. The aqueous material was acidified with aqueous NH4Cl (saturated solution) and 
extracted with DCM. The combined organic layers were dried over MgSO4. The solvent 
was removed in vacuo, and the crude residue was chromatographed on silica gel with 
hexane/EtOAc as eluent to afford the pure product as a white powder (13.6 mg, 0.055 
mmol, 55% yield). 
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The spectral data are identical to (S)-5a. 
HPLC: AD-H column, 95:5 hexanes:isopropanol, 1.00 mL/min, tR = major: 6.5 min, 
minor: 8.1 min. 89% ee. 
 
Preparation of triazole product 
 
8, (R,E)-4-phenyl-1-(4-phenylbut-3-en-2-yl)-1H-1,2,3-triazole 
The title compound was prepared in a procedure modified from Creary and 
coworkers.20 Crude azide 4a (from 0.1 mmol of allene 3a) and phenylacetylene (22 µL, 
0.20 mmol, 2 equiv) were dissolved in a mixture of DCM (1.0 mL) and H2O (0.5 mL) 
and treated with CuSO4 (1.6 mg, 0.010 mmol, 10 mol%) and Na ascorbate (4.0 mg, 0.020 
mmol, 20 mol%). The reaction mixture was stirred for 24 hours at room temperature, 
then the phases were separated, the aqueous layer was extracted with DCM, and the 
combined organic layers were dried over MgSO4. The solvent was removed in vacuo, and 
the crude residue was chromatographed on silica gel with hexane/Et2O as eluent to afford 
the pure product as a white powder (12.2 mg, 0.044 mmol, 44% yield). 
The spectral data are in agreement with those previously reported.13 
HPLC: AD-H column, 95:5 hexanes:isopropanol, 1.00 mL/min, tR = major: 28.8 min, 
minor: 27.6 min. 89% ee. 
 
Reactions with putative catalytic intermediates 
The following reactions were carried out to investigate whether IPrAuN3 and/or 




 To a solution of IPrAuN3 (15.7 mg, 0.025 mmol, prepared analogously to 
SIPrAuN321) in CDCl3/1,4-dioxane-d8 (1:1 volumetric ratio, 1.0 mL) in an NMR tube 
was added allene 3a (3.3 mg, 0.025 mmol). The reaction was monitored periodically by 
1H NMR. No product peaks were observed after 1 day. At that time, water (1.3 µL, 0.072 
mmol) was added via microscale syringe. The reaction was again monitored periodically 





 To a solution of IPrAuOH22 (6.0 mg, 0.010 mmol) and allene 3a (13.0 mg, 0.10 
mmol) in CDCl3 (1.0 mL, 0.1 M) in an NMR tube was added TMSN3 (40 µL, 0.30 mmol) 
and water (3.6 µL, 0.20 mmol) via microscale syringe. The reaction was monitored 
periodically by 1H NMR. No product peaks were observed after 4 days. 
 
Chiral allene racemization studies 
 
A5•(AuCl)2 (3.5 mg, 0.0025 mmol, 5 mol%) or (R)-DTBM-BINAP(AuCl)2 (4.0 
mg, 0.0025 mmol, 5 mol%) and silver triflate (1.9 mg, 0.015 mmol, 15 mol%) were 
weighed in a dram vial and a THF was added (1.0 mL). The heterogeneous mixture was 
sonicated for 5 min using a commercial ultrasonic cleaner, and then filtered through glass 
fiber into a second dram vial containing (S)-3a23 (6.5 mg, 0.05 mmol, 1.0 equiv.) 
Aliquots of 0.15 mL were taken at 5, 30, and 120 minutes. Aliquots were diluted with 
hexane (2 mL) and then passed through a short plug of silica gel, washing with hexanes. 
The solvent was then removed in vacuo and the crude residue was analyzed by HPLC 
(OD-H column, 100% hexanes, 0.25 mL/min). 
 
 A5•(AuCl)2 (R)-DTBM-BINAP(AuCl)2 
5 mins racemic 79% 
30 mins racemic 54% 
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